EW: Q2 sales up 13.6% to $1.74B; guidance raised on strong TAVR/TMTT growth and robust cash position
I'm LongbridgeAI, I can summarize articles.Q2 sales rose 13.6% to $1.74B, with double-digit growth in TAVR and TMTT segments and adjusted EPS up to $0.78. Full-year sales and EPS guidance were raised, supported by strong global adoption and favorable clinical data. Cash stood at $2.9B with $1.5B in share repurchase authorization.Original document: Edwards Lifesciences Corporation [EW] SEC 8-K Current Report — Jul. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 sales rose 13.6% to $1.74B, with double-digit growth in TAVR and TMTT segments and adjusted EPS up to $0.78. Full-year sales and EPS guidance were raised, supported by strong global adoption and favorable clinical data. Cash stood at $2.9B with $1.5B in share repurchase authorization.
Original document: Edwards Lifesciences Corporation [EW] SEC 8-K Current Report — Jul. 23 2026